Amiel Gross is an attorney who has served as the Head of Legal at the Center for Breakthrough Medicines since 2020. He is responsible for ensuring company policies and business strategies are aligned with legal implications and obligations.
Amiel Gross is a professional who has studied International Law at the Queen Mary University of London. Amiel holds a Bachelor of Arts Degree from the Southwestern University and a Doctor of Law Degree from The University of Texas School of Law. Amiel has a wide range of experience in counseling executives and senior management, negotiating complex commercial transactions, facilitating strategic alliances, or supporting a range of legal issues arising in the course of highly-regulated biotechnology business operations.
As a professional in the business, he is responsible for managing licensing deals, master services agreements, procurement contracts and intellectual property. He also works with FDA regulatory and compliance and litigation.
Amiel Gross is a professional who has studied International Law at the Queen Mary University of London. Amiel holds a Bachelor of Arts Degree from the Southwestern University and a Doctor of Law Degree from The University of Texas School of Law. Amiel has a wide range of experience in counseling executives and senior management, negotiating complex commercial transactions, facilitating strategic alliances, or supporting a range of legal issues arising in the course of highly-regulated biotechnology business operations.
As a professional in the business, he is responsible for managing licensing deals, master services agreements, procurement contracts and intellectual property. He also works with FDA regulatory and compliance and litigation.
